Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
|
|
- Samantha Lindsey
- 5 years ago
- Views:
Transcription
1 Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division of Infectious Diseases, UCSF Objectives Establish importance of testing and treatment for latent tuberculosis infection infection (LTBI) Discuss patient populations to be tested Review tests currently available Explore treatment options Discuss diagnosis of active TB PART 1: WHY TEST? 3 4 1
2 Natural History of TB Active vs. Latent Tuberculosis Exposure to infectious TB Not infected 5% Develop primary Latent TB infection (LTBI) 90% Remain latently infected 5% Progression to Reactivation Active TB disease Cough, fever, weight loss, night sweats, hemoptysis Contagious TB cases Latent TB infection No symptoms Not contagious May progress to 10% lifetime risk 10% annual risk among HIV infected Not TB cases 5 6 TB Cases in the United States Reported TB in California, ,000 25,000 20,000 15,000 10,000 5,000 0 First increase in 23 yrs Foreign born 81% US born 19% CDC, Annual Report, 2015 Salinas, et al. MMWR, Each = 1 TB case (Total = 2137) 8 2
3 Consequences of Active TB If TB disease is curable, why is prevention so important? 1. Mortality ~ 10% of patients with TB do not survive Pascopella, Open Forum Infect Dis, Morbidity After treatment, patients have shorter life expectancy Hoger, Int J Tuberc Lung Dis, 2014; Shuldiner, Int J Tuberc Lung Dis, Cost of treating Hospitalization and outpatient case management Balaban, Public Health Rep, Public Health Treatment of latent TB infection reduces future TB transmission 9 >2100 cases per yr How do TB Cases Occur in California? or Why test for latent TB infection? Recent Transmission* Importation 0% 20% 40% 60% 80% 100% * France et al, Am J Epidemiol Reactivation 10 ~10,000 cases of Burden of TB in the U.S. 2.4 Million Estimated TB Infections, California 2014 U.S. Born Foreign Born ~15 million with latent TB infection 0.55 Million 1.85 Million CDC, Annual Report, 2015 Miramontes, PLOS One, 2015 American Community Survey, % 20% 40% 60% 80% 100% Estimated by applying nativity and race/ethnicity specific TB infection prevalence from NHANES (Miramontes, 2015) to the California ACS population estimates using TST for US born and IGRA for foreign 12 born 3
4 Millions of persons Latent TB Infection: Number, awareness, and treatment California, M U.S. born Foreign born Barriers to Treatment of Latent TB Infection Nonspecific guidelines Confusion about which groups should (or should not) be tested and treated Limited resources in busy clinical settings Suboptimal tests and treatment options Not considered an important clinical problem % 12% LTBI prevalence Aware of LTBI Treated for LTBI Estimated using National Health and Nutrition Examination Survey, applied to the California population Part 1: Key Points Most TB cases in the U.S. are due to reactivation and are therefore preventable TB disease remains a substantial contributor to morbidity and mortality Historical barriers have impeded adoption in many practice settings PART 2: WHO TO TEST?
5 Why not test everyone? Natural History of TB Testing populations with low prevalence will result in many false positive results Example: Among low risk U.S. born patients: Risk for infection Exposure to infectious TB Latent TB infection (LTBI) 90% Remain latently infected Prevalence of latent TB infection False positive rate 2.8% 46% Develop primary Risk for progression 5% Progression to Reactivation Miramontes, PLOS One, 2015 Pai, Clin Micro Rev, Who to Test for LTBI? Risk of Exposure (e.g., Foreign born) Risk of Progression (e.g., diabetes) TB Risk Factors Exposure/Infection Progression Foreign born* HIV/AIDS Known contact to infectious case Transplant Homeless Silicosis Corrections Cancer (head/neck) IV drug abuse ESRD on dialysis Long term care facilities Steroids Healthcare workers TNF alpha blockers Diabetes mellitus Underweight Smoking Recent infection 19 *From a country with elevated TB rate CDC, MMWR,
6 Risk Assessment For use by primary care providers Simplicity, clarity over detail A decision to test is a decision to treat Companion Fact Sheet 22 Prioritize if necessary If health system resources do not allow for testing all foreign born persons: Prioritize medical risk for progression 1. Diabetes mellitus 2. Smoker within past 1 year 3. End stage renal disease 4. leukemia or lymphoma 5. Silicosis 6. cancer of head or neck 7. intestinal bypass/gastrectomy 8. chronic malabsorption 9. body mass index California Department of Public Health,
7 US Preventive Services Task Force Population Adults who are at increased risk for tuberculosis: persons born in, or former residents of, countries with increased tuberculosis prevalence persons who live in, or have lived in, high risk congregate settings (such as homeless shelters and correctional facilities) Recommendation Grade The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations that are at increased risk. What about age? Younger persons have longer expected life during which TB progression could occur 25 30% of TB cases in 65+ age group LTBI prevalence increases with age Older age is a risk factor for death if active TB develops No upper limit of age has been set for TB screening recommendation statement144/latent 2tuberculosis infection screening CDC Annual Report, 2015 Miramontes, PLOS One, 2015 Pascopella OFID Years in US at TB Diagnosis California, Years in US at TB Diagnosis California, TB Cases % in US > 5.9 years 50% in US >16 years TB Cases TB rate per 100,000 Years in US 27 Years in US 28 7
8 What about high risk congregate settings? Homeless shelters, corrections Risk and epidemiology can vary Geography, type of facility Regulatory and legal mandates may apply Screening programs integrated into sites Shelter screening programs, corrections screening, occupational health Check with your local public health TB control program Part 2: Key Points Patients should have a TB risk assessment Foreign birth, immunosuppressed, contact A decision to test is a decision to treat Age and years since U.S. entry are not contraindications to testing or treatment Natural History of TB Test 90% Remain latently infected Exposure to infectious TB Latent TB infection (LTBI) PART 3: HOW TO TEST? 5% Develop primary 5% Progression to Reactivation
9 Tuberculin Skin Test (TST) aka PPD Tuberculin Skin Test (TST) Delayed type hypersensitivity reaction How to read: Measure induration (not erythema) at hrs Record millimeters Positive test: 5mm for immunosuppressed including HIV, recent contacts, fibrotic CXR 10mm for all others with TB risk Interferon Gamma Release Assays (IGRAs) QuantiFERON TB Gold (QFT) Reported as positive, negative, or indeterminate T SPOT.TB (T Spot) Reported as positive, borderline, negative, or indeterminate IGRA vs. TST Advantages over TST Not affected by BCG vaccination Not affected by most non tuberculous mycobacteria Interpretation is more objective No return visit needed for interpretation of test Patients and providers may lack confidence in TST results 35 CDC, MMWR, 2010 Pai, Clin Micro Rev,
10 TST and QFT Specificity Specificity 95% confidence interval TST without BCG TST with BCG QFT Testing Foreign Born Patients Using a test with poor specificity will result in many false positive results Example: Among foreign born patients (prevalence 16%): Test False positive rate QFT 12% TST 73% Menzies, Ann Intern Med, 2007 Pai, Ann Intern Med, Pai, Clin Micro Rev, 2014 Miramontes, PLOS One, Diagnosing Latent TB Infection TSTs and IGRAs cannot distinguish between latent TB infection and Latent TB infection?? Positive TST or IGRA Active TB disease must be evaluated Symptom screen + chest radiograph Possible sputum collection: 1. AFB smear and culture 2. TB PCR/NAAT Active TB disease RULE OUT ACTIVE DISEASE BEFORE STARTING LTBI TREATMENT!! Get chest radiograph If abnormal collect sputum If sputum collected: Either start empiric treatment for active disease Or await final culture results before starting LTBI Rx
11 Part 3: Key Points Either IGRA or TST can aid in the diagnosis of latent TB infection Neither test can distinguish between latent TB infection and IGRAs have advantages over TST in certain situations PART 4: HOW TO TREAT? Exposure to infectious TB Natural History of TB 5% Develop primary TST or IGRA Latent TB infection (LTBI) Treatment of LTBI 90% Remain latently infected X 5% Progression to Reactivation Treatment Regimens for Latent TB Infection Medication(s) Frequency Duration Doses Isonizaid (INH) Daily 6 9 months Rifampin Daily 4 months 120 Rifapentine + INH Weekly 3 months
12 Isoniazid (INH) Advantages Gold standard of treatment for latent TB infection Efficacy is 60% 90%, depending on duration of treatment Fewer drug drug interactions Disadvantages Adherence Initiation and completion rates <50% Hepatotoxicity Incidence 0.1%, but increases with age Clinic time required for 9 monthly visits Pl H6 R3 Placebo 6 months INH 3 month Rifampin Nolan, JAMA, 1999 Smieja, Cochrane Database Syst Rev, 2000 Menzies, Ann Int Med, Hong Kong Chest Service/Tuberculosis Research Centre, Am Rev Respir Dis, 1992 Rifampin Advantages: Less hepatotoxicity (~5x less than INH) Greater adherence (78% RIF vs. 60% INH) Disadvantages: Less evidence of efficacy Could be 17% less efficacious than INH and still be cost saving Multiple drug interactions Warfarin, oral contraceptives, methadone, protease inhibitors INH RPT INH No. of patients 3,986 3,745 Frequency Weekly Daily Duration 3 months 9 months Administration Directly observed Self administered Hong Kong Chest Service/Tuberculosis Research Centre, Am Rev Respir Dis, 1992 Villarino, Am J Respir Crit Care Med, 1997 Menzies, Ann Intern Med, 2008 Holland, Am J Respir Crit Care 47 Sterling, NEJM, 2011 Med,
13 Prevent TB Study Results INH RPT INH P value Effectiveness 1.9 per 1, per 1,000 Non inferior Completion 82.1% 69.0% P<0.001 Hepatotoxicity 0.4% 2.7% P<0.001 Further Studies of INH RPT Children ( 2 yrs) Non inferior to 9 months of INH Self administered therapy (SAT) Completion rates: SAT 78% vs. DOT 85% (noninferior) HIV Non inferior to 9 months of INH Unable to receive ART in first 90 days Sterling, NEJM, Villarino, JAMA Pediatrics, 2015 Belknap, CROI, 2015 Sterling, CROI, INH RPT Advantages: Less hepatotoxicity (~ 7x less than INH) Greater adherence (82% INH RPT vs. 69% INH) Disadvantages: Multiple drug interactions Pill burden Flu like syndrome (2.2%) Bliven Sizemore, Int J Tuberc Lung Dis, 2015 Sterling, Clin Infect Dis, Preventing Hepatotoxicity Patient counseling Avoid alcohol and acetominophen Stop if symptoms develop: nausea, anorexia, abdominal pain, jaundice, rash Monitoring Monthly review for symptoms of adverse reactions (1 month supply) Monitor with baseline and periodic LFTs if: Chronic ETOH, viral hepatitis, known liver disease, HIV, pregnant/3 months post partum, other hepatotoxic medications,? > 35 yo Saukkonen Am J Resp Crit Care Med
14 Part 4: Key Points INH is the traditional gold standard, but has extremely low treatment initiation and completion rates Short course regimens have higher completion rates and are less hepatotoxic PART 5: DIAGNOSING ACTIVE TB INH RPT (3 months) is as efficacious as INH (9 months) Clinical Presentation: Signs and Symptoms Cough (dry/productive sputum) 75 80% Weight loss 45 75% Fatigue 60 70% Fever 50 60% Night sweats 50 55% Hemoptysis 25 35% Pleuritic chest pain No symptoms 10 20% Radiographic Patterns of Pulmonary TB Pattern Infiltrate Typical (Reactivation) 85% upper Cavitation Common (20%) Rare in children and primary TB Adenopathy Uncommon More common in children and primary TB Barnes 1988, Miller Effusion May be present 56 14
15 57 4/14/2016 Sputum AFB smear Smear positive 10 4 bacilli per ml Smear AFB amount correlates with infectiousness 40 60% of culture positive cases will be smear negative Three smear negative specimens does not rule out TB! What is the added value of NAAT? For AFB smear ( ): 50 70% of smear /culture + cases will be + by NAAT start treatment (earlier) If NAAT ( ), the likelihood of TB lower Release from isolation earlier (2 Xpert results finds all smear +) Still start treatment if suspicion is high For AFB smear (+): NAAT can confirm TB quickly If NAAT negative, prevent falsely diagnosing TB (likely NTM if inhibitors are ruled out and result repeated) Luetkemeyer Clin Infect Dis Xpert MTB/RIF Test Performance Compared with Culture, U.S. patients Use of NAATs! Smear (+) 96.7% (59/61) Smear ( ) 59.3% (16/27) Sensitivity 1 Xpert 2 Xperts 100% (62/62) 71.4% (20/28) Specificity 99.2% NAAT should be used unless results would not impact clinical or public health management Xpert results showing Rif resistance should: Be confirmed using sequencing and/or culture Trigger suspicion for MDR TB (not Rif monor) Luetkemeyer Clin Infect Dis CDC MMWR October 18, 2013 / 62(41);
16 Summary: Why test? Most TB cases in the U.S. are preventable TB disease still causes substantial morbidity and mortality SUMMARY 15 million persons in the U.S. are infected with TB Summary: Who to test? Patients should have a TB risk assessment Foreign birth, immunosuppressed, contact A decision to test is a decision to treat Age and years since U.S. entry are not contraindications to testing or treatment Summary: How to test? Both IGRAs or TSTs can be used to support the diagnosis of latent TB infection Neither test can distinguish between latent TB infection and IGRAs have advantages over TST in certain situations
17 Summary: How to treat? INH has extremely low treatment initiation and completion rates Short course regimens have higher completion rates and are less hepatotoxic INH RPT (3 months) is as efficacious as INH (9 months) Conclusions Testing and treatment of latent TB infection is crucial to accelerating the decline of TB in the United States New tools can help simplify and improve management of latent TB infection: 1. Simple TB risk assessment 2. IGRAs 3. Short course regimens Acknowledgments Brian Baker Caitlin Reed Local TB Control Programs Jenny Flood Lisa Pascopella Peter Oh Janice Westenhouse Neha Shah Gisela Schecter Use the California TB Risk Assessment 67 References and Resources California DPH TB Control Branch: Risk Assessment: CA TB Risk Assessment and Fact Sheet.pdf INH+Rifapentine Fact Sheet: INH RIF LTBI fact sheet.pdf CDC IGRA Guideline: INH+Rifapentine Guideline: NAAT Guideline: Xpert MMWR: California TB Controllers Association IGRA Guideline: TST in 3D: Curry International Tuberculosis Center (Warmline Consultation Service) or
10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationRevised Technical Instructions for Civil Surgeons. October 9, 2018
Revised Technical Instructions for Civil Surgeons October 9, 2018 Speakers Joanna Regan Centers for Disease Control and Prevention Shereen Katrak California Department of Public Health Pennan Barry California
More informationPediatric Tuberculosis in Los Angeles County: An Update
Pediatric Tuberculosis in Los Angeles County: An Update Julie Higashi, MD PhD Director, Tuberculosis Control Program March 2, 2019 0 Pediatricians will be the driving force of TB elimination in California
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION
TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationAdvanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014
Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,
More informationTB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology
TB EPIDEMIOLOGY TB Clinical Intensive Course Curry International Tuberculosis Center September 30, 2015 Varsha Nimbal, MPH Tuberculosis Control Branch California Department of Public Health 1 Outline TB
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationCoordinating with Public Health on Tuberculosis Testing & Treatment
Coordinating with Public Health on Tuberculosis Testing & Treatment Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Associate Professor University of New Mexico College of Pharmacy Objectives 1. Identify
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationTB Infection Who is Testing and Treating? TB Control and Elimination: Current Dilemma. Span of TB Control: 2010
TB Infection Who is Testing and Treating? Jennifer Flood, M.D., M.P.H. California Department of Public Health Tuberculosis Control Branch Jennifer.Flood@cdph.ca.gov 1 TB Control and Elimination: Current
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTherapy for Latent Tuberculosis Infection
Screening and Treatment of LTBI in TB Control in the US Margarita Elsa Villarino MD MPH Division of TB Elimination, CDC April 14, 2004 TB Prevention and Control in the United States The fundamental strategies
More informationTuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18
Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationTuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013
Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationCommunity pharmacy-based tuberculosis skin testing
Community pharmacy-based tuberculosis skin testing Shanna K. O Connor, PharmD ISU KDHS Spring CE Seminar 2018 In support of improving patient care, Idaho State University Kasiska Division of Health Sciences
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationTB in California: Costs, Transmission, and Selecting from the Latent Pool
TB in California: Costs, Transmission, and Selecting from the Latent Pool Pennan Barry, MD, MPH Tuberculosis Control Branch California Department of Public Health California Tuberculosis Controller s Association
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More informationThe Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination
Four Corners TB and HIV Conference November 3, 2015 Durango, CO The Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationClinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis
Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationTB-Free California: How close are we? How can we get closer?
TB-Free California: How close are we? How can we get closer? California TB Controllers Association April 21, 2015 Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology Section Acknowledgments Local
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More information2017/2018 Annual Volunteer Tuberculosis Notice
Lewis Center for Educational Research Academy for Academic Excellence Norton Science and Language Academy Business Offices 17500 Mana Road Apple Valley, CA 92307 E-mail: hr@lcer.org 760-946-5414 Fax 760-946-9193
More informationExpanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination
IUATLD North American Region Conference February 24, 2017 Vancouver, BC Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationDiagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011 Douglas Hornick, MD has the following disclosures to
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationLatent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers
Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2013 Case 1: 52 y/o male Born in the Pacific Islands; some travel in
More informationTuberculosis Infection in the US Military
Tuberculosis Infection in the US Military Edward Munch. The Sick Child. (1885) Anjali Kunz, MAJ (P), MC Pediatric Infectious Disease, Chief, JBLM Courtesy of : Paul B. Keiser, Feb 2014 Walter Reed Army
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationLatent TB Infection Treatment
Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None
More informationTB Nurse Case Management San Antonio, Texas March 7 9, Clinical Diagnosis and
TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Clinical Diagnosis and Management of LTBI Lynn Horvath, MD March 7, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict
More informationDetection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges
Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationLatent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationLTBI: Who to Test & When to Treat
LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report
More informationPreventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program
Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Topics of Discussion TB Overview Epidemiology of TB in Oregon Annual Facility
More informationTuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED
Tuberculosis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments COL Paul Keiser LTC James E. Moon LTC Jaime Mancuso LTC Anjali Kunz MAJ Kristopher Paolino MAJ Leyi
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationContact Investigation
Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationTB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014
TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with
More informationDisclosures. Current Issues and Controversies in Child and Adolescent Tuberculosis 02/24/2016. NSTC 2016 Annual Meeting
Current Issues and Controversies in Child and Adolescent Tuberculosis Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea Cruz, M.D.] Disclosures Dr.
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lynn Horvath, MD November 11, 2014 Lynn Horvath, MD has the following disclosures to
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationINDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
More informationMichael J. Huey, MD. NYSCHA Annual Meeting WE-2, October 19, 2016
Michael J. Huey, MD Assistant Vice President and Executive Director Emory University Student Health Services Associate Professor, Family and Preventive Medicine Emory University School of Medicine President-elect
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Tuberculosis Pathogenesis and Treatment f Latent TB Infection Lynn Horvath, MD October 15, 2013 Lynn Horvath, MD has the following disclosures to make: No
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationAdvanced Concepts in Pediatric Tuberculosis
Advanced Concepts in Pediatric Tuberculosis: Nizar F. Maraqa, MD, FPIDS Division of Pediatric Infectious Diseases & Immunology University of Florida College of Medicine - Jacksonville Advanced Concepts
More information